The unique antimicrobial wound contact layer with Safetac® technology

- Based on an innovative fusion of Safetac technology and a silver compound to power the dressing benefits.
- Minimal damage to the skin and the wound at dressing changes. Minimal patient pain.¹
- Can be left in place, while a secondary layer is changed more frequently.²
- Inactivates a broad range of wound-related pathogens up to 8 days.³
- Antimicrobial effect – even with a secondary layer.⁴

Safetac technology. Less pain and less trauma.

Safetac technology is a patented adhesive technology. Dressings with Safetac technology are atraumatic upon removal.⁵,⁶,⁷ These dressings minimize trauma to the wound and the surrounding skin, which minimizes pain to the patient.⁸ The risk of maceration is minimized by sealing the wound margins.⁹,¹⁰,¹¹

For more information visit www.molnlycke.ca
How to use Mepitel® Ag

1. Cleanse the wound following normal procedures and dry the surrounding skin thoroughly. Choose a size of Mepitel Ag that covers the wound and the surrounding skin by at least 2 cm, and cut it to fit if needed.

2. While holding the larger protective film, remove the smaller one. Moisten gloves to avoid adherence to Mepitel Ag.

3. Apply Mepitel Ag over the wound.

4. Remove the remaining protective film. Smooth out Mepitel Ag. If more than a piece of Mepitel Ag is needed, the dressings need to be overlapped in such a manner that the open structures are not blocked.

5. Apply an appropriate secondary layer over Mepitel Ag such as Mextra® Superabsorbent or Mesorb®. In contoured areas, ensure there is sufficient padding to keep Mepitel Ag flat against the wound.

6. Keep the dressings in place by using suitable fixation such as Tubifast®.

Indications for use

Mepitel Ag is intended for a wide range of exuding wounds such as skin tears and abrasions, sutured/surgical wounds, partial thickness burns, partial and full thickness grafts, lacerations, diabetic ulcers, venous and arterial ulcers.

Frequency of change

Mepitel Ag may be left in place for up to 8 days depending on the patient, condition of the wound and surrounding skin or as indicated by accepted clinical practice. Duration of treatment is determined by the physician and depends on the wound type and healing conditions.

Precautions:

- Mepitel Ag should be used under the supervision of a qualified health care professional.
- Do not use on patients with a known sensitivity to silver or any other contents of the dressing.
- Clinicians / Healthcare Professionals should be aware that there are very limited data on prolonged and repeated use of silver containing dressings, particularly in children and neonates.
- Mepitel Ag may cause transient discoloration of the wound bed and surrounding skin.
- Frequent or prolonged use of this product may result in permanent discoloration of the skin.
- The silver sulphate component in Mepitel Ag is intended to act as a preservative for the dressing material. It is not intended to treat infection. In the event of clinical infection Mepitel Ag does not replace the need for systemic therapy or other adequate infection treatment.
- Do not use Mepitel Ag during radiation treatment, diathermy or examinations e.g. X-ray or ultrasound.
- Avoid contact with electrodes or conductive gels during electronic measurements, e.g. electrocardiograms (ECG) and electroencephalograms (EEG).
- Other than saline solution or water, the interaction of Mepitel Ag with topical treatments has not been demonstrated.
- The interaction of Mepitel Ag with cleansing agents in combination with Mepitel Ag has not been demonstrated.
- Avoid placing pressure upon the dressing when used on partial thickness burns with high risk of rapid granulation or after facial resurfacing.
- Do not re-use. If reused performance of the product may deteriorate, cross contamination may occur.
- Sterile. Do not use if inner package is damaged or opened prior to use.
- Do not re-sterilise.
- Do not use after expiry date. If the product is used after the expiry date product properties cannot be ensured.
- Avoid placing pressure upon the dressing when used on partial thickness burns with high risk of rapid granulation or after facial resurfacing.
- When used on bleeding wounds or wounds with high viscosity exudate, Mepitel Ag should be covered with a moist absorbent dressing.
- When Mepitel Ag is used for the fixation of skin grafts, the dressing should not be changed before the fifth day post application.
- In the event of clinical infection Mepitel Ag does not replace the need for systemic therapy or other adequate infection treatment.
- Do not use Mepitel Ag during radiation treatment, diathermy or examinations e.g. X-ray or ultrasound.
- Avoid contact with electrodes or conductive gels during electronic measurements, e.g. electrocardiograms (ECG) and electroencephalograms (EEG).
- Other than saline solution or water, the interaction of Mepitel Ag with topical treatments has not been demonstrated.
- The interaction of Mepitel Ag with cleansing agents in combination with Mepitel Ag has not been demonstrated.
- Avoid placing pressure upon the dressing when used on partial thickness burns with high risk of rapid granulation or after facial resurfacing.
- Do not re-use. If reused performance of the product may deteriorate, cross contamination may occur.
- Sterile. Do not use if inner package is damaged or opened prior to use.
- Do not re-sterilise.
- Do not use after expiry date. If the product is used after the expiry date product properties cannot be ensured.
- Avoid placing pressure upon the dressing when used on partial thickness burns with high risk of rapid granulation or after facial resurfacing.
- When used on bleeding wounds or wounds with high viscosity exudate, Mepitel Ag should be covered with a moist absorbent dressing.
- When Mepitel Ag is used for the fixation of skin grafts, the dressing should not be changed before the fifth day post application.

References:


Questions? Contact your local Mölnlycke Health Care Representative at:

1 800 494-5134 www.molnlycke.ca

The Mölnlycke Health Care, Mepitel, Mextra Superabsorbent, Mesorb, Tubifast, and Safetac names and logos are registered trademarks of Mölnlycke Health Care AB.

© 2016 Mölnlycke Health Care, Gamlestadsvagen 3C, Goteborg, Sweden 40252.